Associations - Apoptosis stimulant

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1
Chr t(15;17)	Acute Promyelocytic Leukemia	Chr t(15;17)	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	Alpha1H Sensitive: B - Late Trials Alpha1H Sensitive : B	Alpha1H Sensitive: B - Late Trials Alpha1H Sensitive : B
IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3	tretinoin + arsenic trioxide Sensitive: C3 – Early Trials tretinoin + arsenic trioxide Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	pelareorep Sensitive: C3 – Early Trials pelareorep Sensitive : C3	pelareorep Sensitive: C3 – Early Trials pelareorep Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3	cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive: C3 – Early Trials cytarabine + bortezomib + omacetaxine mepesuccinate Sensitive : C3
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	paclitaxel + pelareorep Sensitive: C3 – Early Trials paclitaxel + pelareorep Sensitive : C3	paclitaxel + pelareorep Sensitive: C3 – Early Trials paclitaxel + pelareorep Sensitive : C3
MGMT unmethylation	Glioblastoma	MGMT unmethylation	Glioblastoma	BAL101553 Sensitive: C3 – Early Trials BAL101553 Sensitive : C3	BAL101553 Sensitive: C3 – Early Trials BAL101553 Sensitive : C3
IDH2 mutation + MYC amplification + MAPRE1 overexpression	Glioblastoma	IDH2 mutation + MYC amplification + MAPRE1 overexpression	Glioblastoma	BAL101553 Sensitive: C4 – Case Studies BAL101553 Sensitive : C4	BAL101553 Sensitive: C4 – Case Studies BAL101553 Sensitive : C4
IDH1 mutation + MYC amplification + MAPRE1 overexpression	Glioblastoma	IDH1 mutation + MYC amplification + MAPRE1 overexpression	Glioblastoma	BAL101553 Sensitive: C4 – Case Studies BAL101553 Sensitive : C4	BAL101553 Sensitive: C4 – Case Studies BAL101553 Sensitive : C4
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression	Acute Promyelocytic Leukemia	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4	cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive : C4
NUP98-RARG fusion	Acute Myelogenous Leukemia	NUP98-RARG fusion	Acute Myelogenous Leukemia	arsenic trioxide Sensitive: C4 – Case Studies arsenic trioxide Sensitive : C4	arsenic trioxide Sensitive: C4 – Case Studies arsenic trioxide Sensitive : C4
CLTC-ALK fusion	Diffuse Large B Cell Lymphoma	CLTC-ALK fusion	Diffuse Large B Cell Lymphoma	arsenic trioxide Sensitive: D – Preclinical arsenic trioxide Sensitive : D	arsenic trioxide Sensitive: D – Preclinical arsenic trioxide Sensitive : D
KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	KRAS mutation + STK11 mutation	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D	pembrolizumab + quaratusugene ozeplasmid Sensitive: D – Preclinical pembrolizumab + quaratusugene ozeplasmid Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D	GZ17-6.02 Sensitive: D – Preclinical GZ17-6.02 Sensitive : D
ABCG2 overexpression	Solid Tumor	ABCG2 overexpression	Solid Tumor	TP-3654 + IT-141 Sensitive: D – Preclinical TP-3654 + IT-141 Sensitive : D	TP-3654 + IT-141 Sensitive: D – Preclinical TP-3654 + IT-141 Sensitive : D
IDH2 mutation	Glioma	IDH2 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
IDH1 mutation	Glioma	IDH1 mutation	Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D	omacetaxine mepesuccinate Sensitive: D – Preclinical omacetaxine mepesuccinate Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pelareorep Sensitive: D – Preclinical pelareorep Sensitive : D	pelareorep Sensitive: D – Preclinical pelareorep Sensitive : D
SLFN11 overexpression	Small Cell Lung Cancer	SLFN11 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D	lurbinectedin Sensitive: D – Preclinical lurbinectedin Sensitive : D
SLFN11 underexpression	Small Cell Lung Cancer	SLFN11 underexpression	Small Cell Lung Cancer	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D

Apoptosis stimulant

Apoptosis stimulant

Associations(43)

Associations
(43)